linjc16/ctgov huggingface dataset:
Copy Number Variation in Prenatal Diagnosis

Study Overview
=================
Brief Summary
-----------------
An observed study is aim to map the CNVs distribution in human genome of Chinese prenatal population. Setting: Prenatal diagnosis center of Taizhou City, Zhejiang Province Patient: total cases of pregnant women needed prenatal genetic diagnosing Methods: karyotype was performed with combined of molecular and cytogenic protocol. Subgroup: molecular karyotyping performed by genomic Chip (CMA) or NGS, the latter including cnv-seq and NIPT. Main outcome: comparison of CNVs distributions in subgroups. Second outcome: comparison of CNVs distributions in demographic dates.

Official Title
-----------------
Copy Number Variation in Prenatal Diagnosis

Conditions
-----------------
Copy Number Variation, Genome

Intervention / Treatment
-----------------
* Diagnostic Test: molecular karyotyping


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: total population need invasival prenatal diagnosis Exclusion Criteria: multipara
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| molecular karyotyping<br> | Diagnostic Test: molecular karyotyping<br>* performed by NGS or CMA chip<br>|
| cytogenic karyotyping<br> | Diagnostic Test: molecular karyotyping<br>* performed by NGS or CMA chip<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparison of CNVs distributions in subgroups | subgroups including CNV-seq (by NGS) and CMA chip | 2016-2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparison of CNVs distributions in demographic dates. | demographic dates including indication of prenatal diagnosis | 2016-2020 |
Assesment of Complications and Surgery Timing in Postcovid Thoracotomy Patients: Single Center Experience

Study Overview
=================
Brief Summary
-----------------
Covid-19 infection has caused delay in many surgeries. Besides Covid -19 infection may be a potential problem in especially major surgeries such as thoracotomies. Surgery timing, complications, intensive care unit stay and vaccination status are important issues that should be learned from post-covid cases.The aim of the study is to learn lessons from post-covid thoracotomy cases.

Detailed Description
-----------------
Patients who had covid-19 infection before thoracotomy were assessed by their datas, Postoperative complications, intensive care unit stay, vaccine status, time period between covid infection and surgery were collected from patients' files and statistical analysis performed.

Official Title
-----------------
Assesment of Complications and Surgery Timing in Postcovid Thoracotomy Patients: Single Center Experience

Conditions
-----------------
Thoracotomy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: undergoing thoracotomy had covid infection before surgery Exclusion Criteria: age under 18 missing data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients who had postoperative complication | number of patients who had postoperative complication | 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thoracotomy, covid infection, complication
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

Study Overview
=================
Brief Summary
-----------------
The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks and 96 weeks.

Official Title
-----------------
A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

Conditions
-----------------
Chronic Hepatitis, Hepatitis B

Intervention / Treatment
-----------------
* Drug: Clevudine
* Drug: Adefovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nucleoside treatment-naïve subjects of either gender, females who are non-pregnant and non-lactating, aged 16 years or older (or the legal age of consent as allowed by local regulations), with compensated hepatic function despite a diagnosis of chronic HBeAg positive hepatitis B infection (i.e., based on serological, virological and histological markers) will be eligible for this study. Subjects with historical biopsies used for entry will have chronic hepatic inflammatory injury at screening (Knodell HAI score ≥ 4 and modified Ishak fibrosis score ≤ 5). If applicable, subjects must cease previous treatment with any form of alpha interferon 12 months prior to baseline. For eligibility, subjects must meet the laboratory criteria for total bilirubin, prothrombin time, serum albumin, platelet count, absolute neutrophil count, ANA titer and have a creatinine clearance of ≥ 50 mL/min. Exclusion Criteria: Subjects participating in a clinical trial or receiving an investigational agent for any reason within 60 days of baseline will be excluded. Subjects with clinically significant concomitant diseases will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Clevudine|nan|
|Drug: Adefovir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatitis B virus, Nucleoside Treatment-Naïve Patients with HBeAg Positive
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors

Study Overview
=================
Brief Summary
-----------------
Multicenter retrospective longitudinal analytical study of patients with neuroendocrine tumors.

Official Title
-----------------
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors.

Conditions
-----------------
Neuroendocrine Tumors, Carcinoma;Endocrine

Intervention / Treatment
-----------------
* Other: Histologically confirmed neuroendocrine tumor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18 years or older and with histologically confirmed neuroendocrine tumors; Metastatic or inoperable disease; Patients with clinical information about the therapies received, including exclusive palliative care. Exclusion Criteria: Lack of data on survival outcomes and/or details on treatments received.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients aged 18 years or older with histologically confirmed neuroendocrine tumor<br>Metastatic or inoperable disease; Patients with clinical information about the therapies received, including exclusive palliative care; | Other: Histologically confirmed neuroendocrine tumor<br>* Patients aged 18 years or older with histologically confirmed neuroendocrine tumor of any grade or site; Metastatic or inoperable disease; Patients with clinical information about the therapies received, including exclusive palliative care;<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate per RECIST 1.1; |  | 2022 | 
| Progression-free survival by RECIST 1.1 from D1 of each treatment; |  | 2022 | 
| Symptom control time | Improvement of symptoms and/or stabilization of radiological disease in non-functioning ENT, at the physician's discretion | 2022 | 
| Incidence of complications of the disease and/or treatments, defined by adverse events |  | 2022 |
Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
After heart surgery, about 30% of patients suffer from atrial fibrillation. Patients are randomized into two groups receiving either potentized Strychnos Nux vomica or placebo under double blind conditions. Postoperatively, ECGs are done to monitor cardiac rhythm.

Detailed Description
-----------------
Preoperatively, patients receive potentized Nux vomica or placebo sublingually. Then, patients are observed regarding atrial fibrillation postsurgical. The difference between the group of patients with and without nux vomica is recorded.

Official Title
-----------------
Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Drug: Nux vomica (active comparator)
* Drug: Placebo (placebo comparator)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients before elective Heart valve - or aortocoronary by pass surgery with heart-lung-machine. Exclusion Criteria: Pregnant patients Patients with preoperative atrial fibrillation and/or hyperthyreosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo globules group<br>Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery. | Drug: Placebo (placebo comparator)<br>* Patients receive Placebo looking similar to active drug<br>* Other names: Placebo globules;|
| Active Comparator: Nux vomica group<br>Patients receive Nux vomica globules made out of sugar sublingually before surgery. | Drug: Nux vomica (active comparator)<br>* Patients receive Nux vomica in a homeopathic potentiation<br>* Other names: Strychnos Nux vomica C200;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of atrial fibrillation after heart surgery with heart lung machine |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nux vomica, homeopathy, heart lung machine, heart surgery, postoperatively studied
Data Therapy Collection to Evaluate Performances of an Automated Insulin Titration Algorithm Compared to Standard Method of Titration

Study Overview
=================
Brief Summary
-----------------
A data collection of blood glucose values, insulin, meal composition will be performed for a period of two months, to evaluate the performances of an automated insulin titration algorithm

Official Title
-----------------
Data Therapy Collection to Evaluate Performances of an Automated Insulin Titration Algorithm Compared to Standard Method of Titration

Conditions
-----------------
Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Person with Type 1 diabetes Treated by basal-bolus therapy with MDI or pump Patient with social security or beneficiary of medical coverage Patient using functional insulin therapy or starting and education course Patient able to read and understand the procedure, and able to express consent for study protocol Exclusion criteria: Patient abusing substances Patient deprived of liberty by judicial or administrative decision, person subject to a legal protection measure, patient having a psychological condition making him unable to follow and understand study protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate the performances of an insulin titration algorithm | to evaluate the performances of an insulin titration algorithm to calculate insulin therapy parameters at the same precision of an expert practitioner | day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measure time-in-range evolution adjustment of insulin therapy parameters | to measure time-in-range evolution before and after adjustment of insulin therapy parameters by practitioner | day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Functional insulin therapy
Plan for Microwave Thermal Field

Study Overview
=================
Brief Summary
-----------------
Develop an intelligent system based on contrast-enhanced ultrasound and clinical information to help doctors automatically obtain ablation parameters (ablation needle number, ablation needle type, ablation time,ablation power) when preparing to use microwave ablation to treat hepatocellular carcinoma

Official Title
-----------------
Research on Intelligent System of Plan for Microwave Thermal Field for Hepatocellular Carcinoma

Conditions
-----------------
Hepatocellular Carcinoma, Ablation

Intervention / Treatment
-----------------
* Procedure: Microwave Thermal guided by Plan for Microwave Thermal Field system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy or clinical diagnosis of HCC Complete clinical information and preoperative CEUS Curative treatment Exclusion Criteria: Palliative care Intolerance to ablation Severe coagulation disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HCC patients guided by Plan for Microwave Thermal Field<br>The plan for HCC patients undergoing microwave ablation would be refer to Plan for Microwave Thermal Field system | Procedure: Microwave Thermal guided by Plan for Microwave Thermal Field system<br>* When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRI within 3 days after ablation | Postoperative MRI is used to determine whether the ablation zone completely covers the tumor and whether the size is appropriate | MRI within 3 days after ablation | 
| local tumor progression | Follow up to observe whether local tumor progression occurs within 6 months after ablation | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hepatocellular Carcinoma, microwave ablation
Efficacy at One Year of Combined Injections of Plasma Rich in Platelets and Hyaluronic Acid in Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
The French Society of Rheumatology cannot rule on the value of intra-articular injections of PRP due to the lack of hindsight and insufficient data. In fact, the injection protocols are very heterogeneous in terms of preparation method, the presence or not of leukocytes, the number of centrifugations, the volume injected, the ultrasound guidance, which makes it difficult to analyze the literature. The investigator objective is therefore to evaluate the effectiveness of combined injections of PRP and hyaluronic acid.

Official Title
-----------------
Efficacy at One Year of Combined Injections of Plasma Rich in Platelets and Hyaluronic Acid in Knee Osteoarthritis

Conditions
-----------------
Knee Osteoarthritis, Hyaluronic Acid, Platelet Rich Plasma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age : > 18 years old Patients benefiting, in the context of knee osteoarthritis, from viscosupplementation alone or from two injections of PRP, in combination with HA, at the Amiens University Hospital. Exclusion Criteria: Patient refusal to use the data Language barrier Age less than 18 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PRP + HA<br>two injections of PRP (plasma rich in platelets ), in combination with HA (hyaluronic acid) | |
| HA alone<br>HA (hyaluronic acid) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of the visual analogue scale (VAS) from the PRP + HA group on the HA alone group |  | up to one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
platelet rich plasma, hyaluronic acid, Knee Osteoarthritis
A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to obtain recurrence rates and long-term safety data for patients who had been treating actinic keratoses on the face and scalp with 5 % Imiquimod Cream in a previous study.

Official Title
-----------------
A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1487-IMIQ Study

Conditions
-----------------
Actinic Keratoses

Intervention / Treatment
-----------------
* Drug: Imiquimod


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 100% clearance of Actinic Keratosis (AK) lesions in the 1487 IMIQ study Exclusion Criteria: used any treatments in the previous treatment area within 24 hours prior to the follow-up visit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Imiquimod 5% cream<br>No investigational treatments were given during this study. | Drug: Imiquimod<br>* No defined treatments were given during this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy | Efficacy was evaluated by counting AK lesions in the previous treatment area. Subjects at the 1-year follow-up visit with recurrence of lesion(s). | one year after completion of study 1487-Imiq | 
| Safety | Safety was evaluated by assessing the area of previous treatment for LSRs and skin quality | one year after completion of study 1487-Imiq | 
| Adverse Events | AEs considered by investigator to be possibly or probably related to the 1487-Imiq study medication were documented and recorded. | one year after completion of study 1487-Imiq | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
1 year follow up
Study of the BDNF-Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal

Study Overview
=================
Brief Summary
-----------------
This study is complementary to the main study Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal  NCT01491347. The purpose of this study is to evaluate the Bdnf gene - Val66Met polymorphism in subjects with alcohol dependence according to their alcohol consumption status 6 months after withdrawal (relapse or abstinence), in relation to the presence of psychiatric co-morbidities.

Official Title
-----------------
Study of the BDNF- Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal

Conditions
-----------------
Alcohol Dependence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participation to the study BDNF serum levels evolution during 6 months after alcohol withdrawal (main study) criteria from the main study Exclusion Criteria: criteria from the main study released or out from the main study before the follow-up at 4 months after withdrawal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| alcohol withdrawal<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of the Bdnf gene Val/Val, Val/Met and Met/Met phenotypes as a function of relapse |  | at the time of inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum BDNF levels variations between inclusion and 6 months later (or 4 months if the participants does not come for the 4 months-follow-up). |  | 6 months after alcohol withdrawal | 
| existence of a psychiatric co-morbidity at the inclusion (major depression, schizophrenia, anxiety disorder) |  | at the time of inclusion | 
| presence of a psychiatric co-morbidity at 6 months after withdrawal (major depression, schizophrenia, anxiety disorder) |  | 6 month after alcohol withdrawal |